CMMB

Chemomab Therapeutics Ltd. [CMMB] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

CMMB Stock Summary

Top 10 Correlated ETFs

CMMB


Top 10 Correlated Stocks

CMMB


In the News

01:32 10 Dec 2023 CMMB

Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC

The FDA bestows Fast Track designation to Chemomab's (CMMB) pipeline candidate, CM-101, for the treatment of primary sclerosing cholangitis. Stock rises.

11:20 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.

07:00 10 Dec 2023 CMMB

Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference

TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

11:43 10 Dec 2023 CMMB

Chemomab (CMMB) Stock Gains 30% on FDA Clearance

There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.

08:25 10 Dec 2023 CMMB

Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment

Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.

12:00 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Present at Upcoming Scientific Conferences

TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.

02:40 10 Dec 2023 CMMB

Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript

Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update

TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.

07:00 10 Dec 2023 CMMB

Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference

TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.

CMMB Financial details

Company Rating
Neutral
Market Cap
6.08M
Income
-33.31M
Revenue
0
Book val./share
1.98
Cash/share
2.4
Dividend
-
Dividend %
-
Employees
20
Optionable
No
Shortable
Yes
Earnings
09 Nov 2023
P/E
-0.16
Forward P/E
-4.45
PEG
-0.01
P/S
-
P/B
0.25
P/C
0.2
P/FCF
-0.24
Quick Ratio
4.05
Current Ratio
4.06
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
-2.96
EPS next Y
-0.11
EPS next Q
2.09
EPS this Y
100.83%
EPS next Y
-96.45%
EPS next 5Y
-96.62%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-8.86%
-
-
-
-
SMA20
-23.53%
SMA50
-45.26%
SMA100
-62.59%
Inst Own
0.1%
Inst Trans
1%
ROA
-115%
ROE
-102%
ROC
-1.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
12.4M
Shs Float
10.05M
-
-
-
-
Target Price
-
52W Range
0.43-5.35
52W High
-
52W Low
-
RSI
35.69
Rel Volume
0.18
Avg Volume
1.33M
Volume
235.54K
Perf Week
-12.45%
Perf Month
-40.27%
Perf Quarter
-71.84%
Perf Half Y
-71.18%
-
-
-
-
Beta
-0.285
-
-
Volatility
0.02%, 0.1%
Prev Close
2.06%
Price
0.49
Change
1.66%

CMMB Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
00.79-0.54-1.21-2.43
Operating cash flow per share
0-0.48-0.48-1.19-1.79
Free cash flow per share
0-0.48-0.48-1.22-1.8
Cash per share
00.511.065.93.51
Book value per share
00.430.985.933.18
Tangible book value per share
00.430.985.933.18
Share holders equity per share
00.430.985.933.18
Interest debt per share
00.160.040.030.05
Market cap
0771.59M304.56M71.58M36.41M
Enterprise value
14.74M755.13M293.31M57.23M23.11M
P/E ratio
028.45-51.36-5.7-1.32
Price to sales ratio
00000
POCF ratio
0-46.88-58.1-5.78-1.79
PFCF ratio
0-46.61-57.68-5.67-1.78
P/B Ratio
051.7528.191.161.01
PTB ratio
051.7528.191.161.01
EV to sales
00000
Enterprise value over EBITDA
1.1627.84-49.31-4.63-0.81
EV to operating cash flow
-1.73-45.88-55.95-4.63-1.13
EV to free cash flow
-1.73-45.62-55.55-4.54-1.13
Earnings yield
00.04-0.02-0.18-0.76
Free cash flow yield
0-0.02-0.02-0.18-0.56
Debt to equity
00.070.040.010.01
Debt to assets
00.060.030.010
Net debt to EBITDA
1.16-0.611.891.160.47
Current ratio
04.42923.666.18
Interest coverage
06.4200-80.83
Income quality
00.610.880.990.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.010.010.020
Capex to revenue
00000
Capex to depreciation
0-0.34-1.58-7.03-1.17
Stock based compensation to revenue
00000
Graham number
02.773.4512.713.19
ROIC
01.58-0.51-0.2-0.76
Return on tangible assets
-0.91.37-0.48-0.2-0.64
Graham Net
00.380.893.442.93
Working capital
-14.74M14.09M10.52M60.04M34.99M
Tangible asset value
-14.74M14.91M10.8M61.47M36.22M
Net current asset value
-14.74M13.37M10.17M59.8M34.9M
Invested capital
00.070.040.010.01
Average receivables
0204K241K800.5K993K
Average payables
0046.5K714.5K1.51M
Average inventory
00-328.5K-24.08M-23.75M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
01.82-0.55-0.2-0.76
Capex per share
000-0.02-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.54-0.73-0.72-0.79-0.72
Operating cash flow per share
-0.5-0.46-0.5-0.65-0.68
Free cash flow per share
-0.5-0.46-0.5-0.65-0.68
Cash per share
4.534.063.492.962.4
Book value per share
4.543.93.172.531.98
Tangible book value per share
4.543.93.172.531.98
Share holders equity per share
4.543.93.172.531.98
Interest debt per share
-0.020.040.05-1.590.01
Market cap
42.21M28.48M36.6M17.57M14.63M
Enterprise value
32.61M17.99M23.3M-3.02M4.39M
P/E ratio
-1.7-0.86-1.11-0.5-0.46
Price to sales ratio
00000
POCF ratio
-7.4-5.42-6.42-2.44-1.95
PFCF ratio
-7.39-5.38-6.42-2.44-1.95
P/B Ratio
0.810.641.010.630.67
PTB ratio
0.810.641.010.630.67
EV to sales
00000
Enterprise value over EBITDA
-5.23-2.17-2.70.33-0.54
EV to operating cash flow
-5.72-3.42-4.090.42-0.59
EV to free cash flow
-5.71-3.4-4.080.42-0.59
Earnings yield
-0.15-0.29-0.23-0.5-0.54
Free cash flow yield
-0.14-0.19-0.16-0.41-0.51
Debt to equity
0.010.010.010.010.01
Debt to assets
0000.010
Net debt to EBITDA
1.541.261.542.281.25
Current ratio
12.488.96.184.834.06
Interest coverage
13.03-35.09-22.740.510
Income quality
0.920.650.690.820.94
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000
Capex to revenue
00000
Capex to depreciation
-0.79-2.47-0.07-0.06-0.13
Stock based compensation to revenue
00000
Graham number
7.457.997.186.715.67
ROIC
-0.11-0.19-0.24-0.32-0.37
Return on tangible assets
-0.11-0.17-0.19-0.25-0.28
Graham Net
2.372.062.921.81.85
Working capital
50.44M43.25M34.99M26.78M20.88M
Tangible asset value
51.84M44.62M36.22M27.95M21.99M
Net current asset value
50.29M43.13M34.9M26.72M20.85M
Invested capital
0.010.010.010.010.01
Average receivables
2.52M2.68M1.36M727K1.02M
Average payables
1.46M1.34M1.47M1.95M2.28M
Average inventory
-45.23M-41.47M-18.99M-6.47M-6.47M
Days sales outstanding
00000
Days payables outstanding
20.6213.49022.050
Days of inventory on hand
-646.82-411.030-128.660
Receivables turnover
00000
Payables turnover
4.366.6704.080
Inventory turnover
-0.14-0.220-0.70
ROE
-0.12-0.19-0.23-0.31-0.36
Capex per share
00000

CMMB Frequently Asked Questions

What is Chemomab Therapeutics Ltd. stock symbol ?

Chemomab Therapeutics Ltd. is a IL stock and trading under the symbol CMMB

What is Chemomab Therapeutics Ltd. stock quote today ?

Chemomab Therapeutics Ltd. stock price is $0.49 today.

Is Chemomab Therapeutics Ltd. stock public?

Yes, Chemomab Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap